In Mexico, the pledge of new President Ernesto Zedillo Ponce de Leon to undertake a major restructuring of the health care sector as a priority has been dealt a very significant blow by the sharp devaluation of the peso.
Observers expect, at best, serious delays in the implementation of the ambitious projects announced by the president when he was inaugurated on December 1, 1994, for a six-year term. He has called for a 60-day moratorium on price rises, but these have continued to move up despite fines and temporary business closures. Cuts in government spending and the freeze on salaries will inevitably affect drug prices; even before devaluation, they rose 50%-100% in 1994. Moreover, with a large share of drugs on the market containing ingredients from overseas, further sharp price rises are expected in the near future.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze